drugset / Trial / NCT03168984

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects

NCT03168984

Phase 1 Completed 48 enrolled UCB Biopharma S.P.R.L.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of UCB0942 in Japanese and Caucasian subjects.

Timeline

Start
2017-05-05
Primary completion
2017-08-14
Completion
2017-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Padsevonil Small molecule Oral

Indications

No indication recorded.